Search - tctmd.com

Displaying 61 - 80 of 294

Sort: Relevancy | Date

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Do We Have Enough Data to Make PCI vs CABG Decisions in Complex CAD Using FFR?

Presenter: Fernando Alfonso, Patrick W. Serruys, William F. Fearon

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh

October 30, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

The CADence Device in the Physiologic Evaluation of Acoustic Coronary Turbulence

Presenter: Bernard De Bruyne, Evelyn S. Regar, Joseph Thomas

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Presenter: C. Michael Gibson, Stephan Windecker, Eric R. Bates

October 30, 2017

Presentation TCT 2017

Interventional Pharmacology Strategies for PCI and ACS

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Piera Capranzano

October 29, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

Presentation TCT 2017

Interventional Pharmacology: A Guideline-based Review

Presenter: Jose de Ribamar Costa Jr, Jose L. Leiva-Pons, Dominick J. Angiolillo

October 29, 2017

Advertisement

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Do We Have Enough Data to Make PCI vs CABG Decisions in Complex CAD Using FFR?

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Live From Denver: TCT 2017, Day One

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

The CADence Device in the Physiologic Evaluation of Acoustic Coronary Turbulence

Predicting the Future: Will the Ongoing TWILIGHT and GLOBAL LEADERS Trials Change The Current Recommended Approach to Chronic Antiplatelet Therapy?

Interventional Pharmacology Strategies for PCI and ACS

TCTMD’s Top 10 Most Popular Stories for October 2017

Interventional Pharmacology: A Guideline-based Review

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content